Thanks for your post.
It would be very reasonable to resume a previously successful regimen.
That said, the regimen of ZDV/3TC (Combivir) and nelfinavir (Viracept) is dated and no longer part of treatment guidelines. Combivir remains an effective twice-daily option (especially since your patient tolerated this in the past) that is part of guidelines. Other once-daily nuke combos, such as Truvada or Epzicom are more commonly prescribed.
Unboosted protease inhibitors have been replaced by more potent and better tolerated once-daily ritonavir-boosted options, like atazanavir (Reyataz) and fosamprenavir (Lexiva, Telzir). In our patients and in clinical trials, once-daily lopinavir/ritonavir isn't as well tolerated; it's pretty unusual for us to start patients on once-daily Kaletra.
BY
